Dashboard
Manage Tickers

BAYRY Bayer Aktiengesellschaft


$ -0.14 (-1.77 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 585.60 $ -26.07 (-4.26 %)
DIA $ 458.34 $ -8.34 (-1.79 %)
SPY $ 652.82 $ -20.08 (-2.98 %)
TLT $ 89.28 $ 0.29 (0.33 %)
GLD $ 374.67 $ -0.51 (-0.13 %)
$ 7.77
-- x --
-- x --
-- - --
$ 4.77 - $ 8.70
724,601
na
nm
$ 0.57
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-signs-off-on-bayers-new-lung-cancer-drug--early-results-look-promising
FDA Signs Off On Bayer's New Lung Cancer D...
11/20/2025 17:53:24

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options f...

Core News & Articles
FDA Grants Accelerated Approval To Sevaber...
11/19/2025 19:45:17

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-

Core News & Articles
Siemens Warns Currency Headwinds Will Hit ...
11/14/2025 12:24:08

agricultural-conglomerate-bayer-confident-in-long-term-outlook-despite-litigation-risks
Agricultural Conglomerate Bayer Confident ...
11/12/2025 18:34:51

Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company&#...

Core News & Articles
Bayer Raises FY2025 Sales Guidance from $5...
11/12/2025 12:40:19

Bayer (OTC:BAYRY) raises FY2025 sales outlook from $52.154 billion-$54.422 billion to $53.784 billion-$56.123 billion.

Core News & Articles
Bayer Q3 Adj. EPS $0.17 Up From $0.07 YoY,...
11/12/2025 12:40:04

Bayer (OTC:BAYRY) reported quarterly earnings of $0.17 per share. This is a 142.86 percent increase over earnings of $0.07 per ...

exelixis-stock-falls-after-phase-3-colorectal-cancer-trial-shows-mixed-results
Exelixis Stock Falls After Phase 3 Colorec...
10/20/2025 14:48:53

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...

agri-science-giant-corteva-eyes-breakup-to-shield-seed-unit-from-future-risks-report
Agri-Science Giant Corteva Eyes Breakup To...
09/15/2025 11:49:14

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...

Core News & Articles
Bayer Q2 Adj. EPS $0.35 Beats $0.24 Estima...
08/06/2025 12:54:36

Bayer (OTC:BAYRY) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.24 by 45.83 pe...

exelixis-zanzalintinib-combo-boosts-survival-in-colorectal-cancer-stock-soars
Exelixis' Zanzalintinib Combo Boosts Survi...
06/23/2025 14:37:05

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety c...

bayer-profit-drops-35-launches-overhaul-to-counter-generic-pressure
Bayer Profit Drops 35%, Launches Overhaul ...
05/13/2025 19:26:54

Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwin...

Core News & Articles
Bayer Q1 Adj. EPS $0.65 Beats $0.38 Estima...
05/13/2025 12:20:18

Bayer (OTC:BAYRY) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.38 by 71.05 pe...

fda-grants-complete-approval-to-bayers-drug-for-certain-type-cancer-with-mutation
FDA Grants Complete Approval To Bayer's Dr...
04/10/2025 21:02:19

Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive pa...

bayer-ceo-2025-will-be-most-difficult-year-in-turnaround-plan-expects-improved-performance-from-2026-onwards
Bayer CEO: 2025 Will Be 'Most Difficult' Y...
03/05/2025 16:52:32

Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, wi...

Core News & Articles
Bayer Sees FY2025 Adj EPS $4.80-$5.33 vs $...
03/05/2025 11:14:33

Bayer (OTC:BAYRY) is looking for FY2025 Adj EPS of $4.80-$5.33 vs $4.62 analyst estimate. sees sales of $48.250 billion-$50.239...

Core News & Articles
Bayer Q4 Adj $0.28 Misses $1.00 Estimate, ...
03/05/2025 11:13:12

Bayer (OTC:BAYRY) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $1.00 by 72 per...

regenerons-best-selling-eye-drug-eyleas-higher-dose-formulation-meets-primary-goal-in-another-form-of-retinal-disease-study
Regeneron's Best-Selling Eye Drug Eylea's ...
12/17/2024 18:05:27

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA sub...

fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market
FDA Approves BridgeBio Pharma's Drug For R...
11/25/2024 14:03:46

FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks ...

bridgebio-pharmas-acoramidis-shows-competitive-edge-against-pfizers-tafamidisa-in-lucrative-but-competitive-attr-cm-market
BridgeBio Pharma's Acoramidis Shows Compet...
11/19/2024 19:44:59

BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safe...

Core News & Articles
Cytokinetics And Bayer Partner For Exclusi...
11/19/2024 07:44:52

Approximately €70 Million in Upfront and Near-term Payments to CytokineticsUp to €490 Million in Commercial Milestone Payments,...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION